Vistagen Regulatory Tuesday, September 22, 2026 +0.75 Positive

Vistagen Reports Positive Safety and Efficacy Data from PALISADE-4 Study

Preliminary OLE data shows fasedienol nasal spray was well-tolerated and clinically improved social anxiety symptoms over four months, contributing to its potential for everyday use.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed